Seeking Alpha reiterated a buy rating for Tempus AI on September 22, 2026, citing a 60% rally since its last analysis. The report highlighted robust growth in oncology testing volumes. Oncology testing volumes increased 31% year-over-year in Q2 2026. MRD test volumes nearly doubled since Q4 2025. This growth validates the recent acquisition of Personalis.
The data and applications segment was a key growth driver, increasing 28% in Q2. The company also raised its full-year revenue guidance.
Recent developments include an initiative to build the largest multimodal whole-genome dataset. Tempus AI also received FDA clearance for an AI-powered software to detect pulmonary hypertension.